The FDA approval of palbociclib for treatment of ER-positive, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ErbB2)-negative breast cancer patients was a major breakthrough [66,67,68]. The gene discussed is ERBB2; the disease is breast carcinoma.